Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori Infection

Internal Medicine

Volumn 50, Issue 5, 2011, Pages 369-374

  Furuta, Takahisa ^a   Kato, Mototsugu ^b   Sugimoto, Mitsushige ^a   Sasaki, Makoto ^c   Kamoshida, Toshiro ^d   Furukawa, Kouichi ^e   Inaba, Tomoki ^f   Tomita, Takashige ^g   Shirai, Takayuki ^h   Ishii, Naoki ⁱ   Nomura, Hideyuki ^j   Konda, Yoshitaka ^k   Asaka, Masahiro ^l  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Hitachi General Hospital   (Japan)

^e NIIGATA CITY GENERAL HOSPITAL   (Japan)

^f KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^g Shinagawa ku   (Japan)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^j Shin Kokura Hospital   (Japan)

^k Higashiyama Takeda Hospital   (Japan)

^l HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Clarithromycin; Ecabet sodium; Eradication; H. pylori; Metronidazole; Resistance

Indexed keywords

12 SULFODEHYDROABIETIC ACID; AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOT FLUSH; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DITERPENES, ABIETANE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

EID: 79952358825     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4305     Document Type: Article

References (28)

1. Wotherspoon AC. Helicobacter pylori infection and gastric lymphoma. Br Med Bull 54: 79-85, 1998.
2. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789, 2001.
3. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective doubleblind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2: 1437-1442, 1988.
4. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 275: 622-629, 1996.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167-180, 2002.
6. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 6: 254-261, 2001.
7. Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for secondline Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 17: 119-123, 2003.
8. Tokunaga K, Tanaka A, Sugano H, Takahashi S. The present status and problems of Helicobacter pylori first-line eradication therapy. Nippon Rinsho 67: 2291-2296, 2009 (in Japanese).
9. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 81: 521-528, 2007.
10. Nagahara A, Miwa H, Kawabe M, et al. Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitorbased amoxicillin and metronidazole regimen. J Gastroenterol 39: 1051-1055, 2004.
11. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55: 1711-1716, 2006.
12. Ito Y, Nakamura S, Onoda Y, Sugawara Y, Takaiti O. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein. Jpn J Pharmacol 62: 169-174, 1993.
13. Kinoshita M, Yamasaki K, Kokusenya Y, Tamaki H. Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats. Comparison with sucralfate. Dig Dis Sci 40: 661-667, 1995.
14. Kinoshita M, Endo M, Yasoshima A, et al. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Aliment Pharmacol Ther 13: 687-694, 1999.
15. Ito Y, Shibata K, Hongo A, Kinoshita M. Ecabet sodium, a locally acting antiulcer drug, inhibits urease activity of Helicobacter pylori. Eur J Pharmacol 345: 193-198, 1998.
16. Shibata K, Ito Y, Hongo A, Yasoshima A, Endo T, Ohashi M. Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 39: 1295-1299, 1995.
17. Furuta T, Soya Y, Sugimoto M, et al. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J Gastroenterol Hepatol 22: 1810-1815, 2007.
18. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol 93: 386-389, 1998.
19. Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 28: 325-326, 1994.
20. Bradley WG, Karlsson IJ, Rassol CG. Metronidazole neuropathy. Br Med J 2: 610-611, 1977.
21. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23: 35-44, 2006.
22. Ohkusa T, Takashimizu I, Fujiki K, et al. Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 12: 457-461, 1998.
23. Kagaya H, Kato M, Komatsu YM, et al. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther 14: 1523-1527, 2000.
24. Kim HW, Kim GH, Cheong JY, et al. H. pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 14: 908-912, 2008.
25. Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108: 1412-1417, 1995.
26. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11: 341-348, 2001.
27. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17: 479-501, 2003.
28. Craig WA. Proof of concept: performance testing in models. Clin Microbiol Infect 10 (Suppl 2): 12-17, 2004.